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論 文 内 容 の 要 旨 
 
 Increasing evidence indicates that lymphangiogenesis plays an important role in promoting 
tumor progression and metastasis. The discovery of immunohistochemical markers for the 
identification of lymphatic vessels, as well as the characterization of lymphatic-speciﬁc growth 
factors and receptors, has provided insight into the mechanisms involved in new lymphatic 
vessel formation and the process of metastasis via the lymphatic system.Quantitative assessment 
of lymphangiogenesis in malignant tumors has emerged as a promising prognostic indicator. 
However, the results are conflicting regarding the usefulness of lymphatic vessel density for 
predicting lymph nodal metastases and overall survival. Solid tumors were recently found to 
induce new lymphatic vessel growth in draining lymph nodes before the onset of metastasis; 
this has generated immense interest in studying lymphangiogenesis in the lymph nodes. 
The vascular system plays important roles in supplying fresh oxygen and nutrients to tissues 
while the lymphatic system plays pivotal roles in mediating tissue fluid homeostasis and 
immunity. Excessive formation of blood and lymphatic vessels is also implicated in many 
pathological conditions, including inflammation and tumor metastasis, as tumor cells 
metastasize to other distant organs via newly formed blood and lymphatic vessels. Therefore, 
angiogenesis, lymphangiogenesis, and lymph node metastasis are very important diagnostic 
indicators for the prediction of tumor progression.  
In this study, we demonstrated the effects of deoxyshikonin on lymphangiogenesis. 
Deoxyshikonin enhanced the ability of human dermal lymphatic microvascular endothelial cells 
(HMVEC-dLy) to undergo time-dependent in vitro cord formation.The increased ability for 
cord formation following deoxyshikonin treatment correlated with increased expression of 
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VEGF-C mRNA, compared to VEGF-A and VEGF-D mRNA expression. Deoxyshikonin also 
regulated cord formation of HMVEC-dLy cells by increasing the HIF-1𝛼 mRNA level, HIF-1𝛼 
protein level, and the accumulation of HIF-1𝛼 in the nucleus. Knockdown of the HIF-1𝛼 gene 
by transfection with siHIF-1𝛼 decreased VEGF-C mRNA expression and cord formation ability 
in HMVEC-dLy. Deoxyshikonin treatment could not restore VEGF-C mRNA expression and 
cord formation ability in HIF-1𝛼 knockdown cells.This indicated that the deoxyshikonin 
induction of VEGF-C mRNA expression and cord formation in HMVEC dLy on Matrigel 
occurred mainly via HIF-1𝛼 regulation. 
Deoxyshikonin also promoted in vitro wound healing by the induction of HMVEC-dLy 
migration into the wound gap. This study describes a new effect of deoxyshikonin, namely, the 
promotion of cord formation by human endothelial cells via the regulation of HIF-1𝛼. The 
findings suggest that deoxyshikonin may be a new drug candidate for wound healing and 
treatment of lymphatic diseases. 
The effects of shikonin on in vitro lymphangiogenesis were also examined. First, its effects 
were evaluated in temperature-sensitive rat lymphatic endothelial (TR-LE) cells. A WST-8 
assay indicated that shikonin induced viability of TR-LE cells. Adhesion increased in 
shikonin-treated TR-LE cells compared to control cells. Capillary formation also decreased in 
the shikonin-treated TR-LE cells, with the strongest suppression observed at 4 h. However, no 
effect was observed on cell migration. The effects of shikonin were also tested on in vitro 
lymphangiogenesis in human endothelial cells (human dermal lymphatic microvascular 
endothelial cells, HMVEC-dLy)and reduced capillary formation in the shikonin-treated cells 
was observed. 
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Our study demonstrated in vitro anti-lymphangiogenetic effects of shikonin for 
the first time. These results suggest that shikonin may be a new drug candidate for 
treatment of cancer metastasis to the lymph nodes. 
  
